CVS Caremark expanded coverage for Eli Lilly’s oral obesity therapy Foundayo and changed preference dynamics for injected GLP-1 products, adding Foundayo to formularies June 1 and re-adding Zepbound as a preferred option starting Oct. 1. Novo’s Wegovy remains preferred under the plan. The update is intended to rebalance access after CVS previously gave Wegovy an edge, with analysts citing a meaningful expansion of the addressable prescription pool for Lilly’s portfolio. Lilly said the move brings Foundayo and Zepbound to coverage across all three major U.S. PBMs. For the market, the change reinforces how formulary placement is becoming a decisive variable in the commercial trajectory of oral and injectable incretin therapies, particularly as competition intensifies beyond the current leaders. Near-term outcomes to watch include employer-level formulary carveouts and the real-world prescription adoption pace for Foundayo compared with oral peers.